After-Hours Stock Movers 01/27: (EYPT) (AGTC) (NOW) Higher; (AMC) (AXDX) (EXPR) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
EyePoint Pharmaceuticals (EYPT) Reports First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for Treatment of Wet AMD
January 28, 2021 7:10 AM ESTEyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) today announced that the first patient has been dosed in the Phase 1 clinical trial of EYP-1901 as a potential twice-yearly sustained delivery anti-VEGF treatment targeting wet age-related macular degeneration (wet AMD).
EYP-1901 leverages the Companys proprietary Durasert® drug delivery technology that has been used in four FDA-approved products, including EyePoints YUTIQ® for chronic non-infectious uveitis affecting the posterior segment of the eye. EYP-1901 uses a bioerodible Durasert formulation combined with a clinically validated anti-VEGF molecule, vorolanib. In oral formulation, vorolanib demonstrated efficacy and... More
ServiceNow (NOW) PT Raised to $610 at Mizuho Securities
January 28, 2021 6:35 AM ESTMizuho Securities analyst Gregg Moskowitz raised the price target on ServiceNow (NYSE: NOW) to $610.00 (from $600.00) while maintaining a Buy rating.
The analyst commented, "NOW reported a very good 4Q, led by subscription billings growth of roughly 40% that easily beat consensus estimates of... More
